Journey Medical (NASDAQ:DERM) Stock Rating Reaffirmed as Buy by B. Riley Financial

Journey Medical (NASDAQ:DERM – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at B. Riley Financial in a report released on Friday, Benzinga reports. They currently have a $13.00 target price on the stock, down from their prior target price of $15.00. B. Riley Financial‘s price objective suggests a potential upside of 200.23% from the stock’s current price.

Several other research analysts have also recently weighed in on DERM. Wall Street Zen cut shares of Journey Medical from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Journey Medical in a research report on Monday, October 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.00.

View Our Latest Stock Report on DERM

Journey Medical Price Performance

Shares of NASDAQ DERM traded down $0.06 during trading on Friday, reaching $4.33. The company had a trading volume of 387,161 shares, compared to its average volume of 185,290. Journey Medical has a 52 week low of $4.00 and a 52 week high of $9.56. The business’s 50 day moving average price is $5.89 and its 200-day moving average price is $6.47. The stock has a market cap of $122.19 million, a PE ratio of -24.05 and a beta of 1.14. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59.

Journey Medical (NASDAQ:DERM – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The company had revenue of $18.97 million for the quarter, compared to the consensus estimate of $20.32 million. Journey Medical had a negative net margin of 7.34% and a negative return on equity of 16.15%. Analysts expect that Journey Medical will post -0.13 earnings per share for the current year.

Hedge Funds Weigh In On Journey Medical

Several large investors have recently bought and sold shares of DERM. Wasatch Advisors LP boosted its stake in Journey Medical by 34.0% in the second quarter. Wasatch Advisors LP now owns 2,858,930 shares of the company’s stock valued at $20,241,000 after acquiring an additional 725,560 shares during the last quarter. Punch & Associates Investment Management Inc. acquired a new stake in Journey Medical during the 2nd quarter worth $3,795,000. Pale Fire Capital SE grew its holdings in Journey Medical by 9.7% during the 2nd quarter. Pale Fire Capital SE now owns 528,584 shares of the company’s stock worth $3,742,000 after acquiring an additional 46,597 shares during the period. First Eagle Investment Management LLC bought a new stake in shares of Journey Medical during the 3rd quarter valued at $3,305,000. Finally, Marshall Wace LLP raised its position in shares of Journey Medical by 38.9% during the 3rd quarter. Marshall Wace LLP now owns 194,311 shares of the company’s stock valued at $1,329,000 after acquiring an additional 54,468 shares during the last quarter. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical News Roundup

These are some of the DERM news items that stood out recently:

  • Positive Sentiment: Journey Medical’s third-quarter loss narrowed and revenue increased, and a report said shares gained in after-hours trading following the results. Article
  • Neutral Sentiment: B. Riley reaffirmed its “Buy” rating but cut its price target to $13 from $15. The lower target is a cautionary change, though it remains well above the $4.48 reference price cited in the report. Article
  • Negative Sentiment: Quarterly adjusted loss was $0.05 per share, worse than the $0.02 loss analysts expected. Revenue of $18.97 million also missed the $20.32 million consensus, which could weigh on sentiment despite the year-over-year improvement. Earnings report

About Journey Medical

(Get Free Report)

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.

Recommended Stories

Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.